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Abstract The nitric oxide donor, glyceryl trinitrate (GTN),
is a candidate treatment for the management of acute stroke
with haemodynamic and potential reperfusion and neuro-
protective effects. When administered as a transdermal
patch during the acute and subacute phases after stroke,
GTN was safe, lowered blood pressure, maintained cere-
bral blood flow, and did not induce cerebral steal or alter
functional outcome. However, when given within 6 h of
stroke onset, GTN reduced death and dependency (odds
ratio 0.52; 95% confidence interval 0.34–0.78), death,
disability, cognitive impairment and mood disturbance, and
improved quality of life (data from two trials, n = 312). In
a pooled analysis of four studies (n = 186), GTN reduced
between-visit systolic blood pressure variability over days
1–7 compared with no GTN (mean difference -2.09; 95%
confidence interval -3.83 to -0.35; p = 0.019). The
efficacy of GTN given in the ultra-acute/pre-hospital set-
ting is currently being assessed and, if found to be bene-
ficial, the implications for hyperacute stroke practice are
significant. Here, we discuss the evidence to date, potential
mechanisms of action and future possibilities, including
unanswered questions, for the therapeutic potential of GTN
in acute stroke.
Key Points
Transdermal glyceryl trinitrate is safe in patients
with acute stroke.
Glyceryl trinitrate may improve outcome if
administered within 6 h of stroke onset.
The implications for clinical practice are substantial
if efficacy is confirmed. An inexpensive and
effective treatment for hyperacute stroke could be
adopted globally in low-, middle- and high-income
countries.
1 Introduction
Nitric oxide (NO) is a diatomic highly reactive gas. It is an
obligate molecule in health and disease with a multitude of
actions. NO has vasodilatory, pro-endothelial, anti-prolif-
erative (vascular smooth muscle cell) [1], antiplatelet
[2, 3], anti-leucocyte [4], anti-inflammatory, neuroprotec-
tive, neurotransmitter and neuromodulator [5, 6] properties.
It has roles in modulating blood–brain barrier integrity,
cerebral blood flow (CBF), auto- and chemo-regulation
[7–9], and inhibition of apoptosis [10]. NO is an endoge-
nous inorganic soluble gas synthesised from L-arginine by
three forms of NO synthase (NOS): endothelial (eNOS);
inducible (iNOS); and neuronal (nNOS) [11, 12]. The
second messenger cyclic guanosine monophosphate, which
is broken down by phosphodiesterase, is the main mediator
of downstream signalling of NO. NO is broken down via
oxidation to nitrite and ultimately nitrate, and it is now
apparent that NO may be made by reduction of nitrite and
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nitrate. Up-regulation of the L-arginine/nitrite-NO-cyclic
guanosine monophosphate pathway can be achieved by a
number of means: increased substrate, administration of
NO gas, induction of NO synthase activity; administration
of NO donors; or inhibition of phosphodiesterase [13].
Pre-clinical experimental studies in models of ischaemia
have demonstrated the role of NO in a time-dependent
manner. Models of focal ischaemia have shown that NO
production is increased, through nNOS activation, for up to
half an hour after middle cerebral artery occlusion [14, 15].
During the first minutes following arterial occlusion, eNOS
and nNOS activity increases, then falls thereafter [16]. Up
regulation of iNOS occurs from 12 h after the onset of
ischaemia and persists for up to 7 days [17], whilst NO
within brain tissue is undetectable during this period [14].
L-arginine administered intravenously following middle
cerebral artery occlusion in a rat model improved ischae-
mic penumbral blood flow and reduced infarct size and
volume [18]. This effect was not seen in eNOS-deficient
mice who developed smaller penumbral regions, larger
infarcts and absent angiogenesis leading to further post-
ischaemic injury [19–21]. Therefore, eNOS and eNOS-
derived NO are neuroprotective in focal ischaemia, whilst
nNOS- and iNOS-derived NO have deleterious effects on
tissue survival with resultant poor neurological outcomes
[15, 22]. Although neurotoxic in acute stroke, iNOS and
nNOS are involved in neurogenesis following stroke
[23, 24]. In therapeutic studies, NO donors reduced infarct
size in both permanent and transient models of ischaemia,
and increased cerebral blood flow in permanent models, but
only if administered soon after stroke induction [25].
Blood pressure (BP) is high in 75% of people with acute
stroke [26] and is associated independently with poor
functional outcome and increased death (regardless of
stroke type) [27, 28], stroke recurrence in ischaemic stroke
(IS) [29] and haematoma expansion in intracerebral
haemorrhage (ICH) [30]. High admission BP has been
associated with lower rates of recanalisation in IS patients
treated with thrombolysis [31], and with increased infarct
volume and poor functional outcome in patients with large
vessel occlusion [32]. Modulation of BP in acute stroke has
long been debated; treatment of raised BP in ICH is rec-
ommended [33], and is safe in IS [34, 35].
Owing to the myriad effects of NO described above and
the low levels of endogenous NO seen in both IS and ICH
[36, 37], supplementation through administration of NO
donors might be beneficial. In contrast, diaspirin cross-
linked haemoglobin reduces vascular NO levels [38]. In
acute IS, diaspirin cross-linked haemoglobin was associ-
ated with poor neurological outcome. Hence, lowering NO
can lead to worse outcomes in acute stroke, whilst
increasing NO may be beneficial [39]. Here, we discuss the
evidence to date, potential mechanisms of action and future
possibilities, including unanswered questions, for the
therapeutic potential of the NO donor glyceryl trinitrate
(GTN) in acute stroke.
2 Nitric Oxide Donors and Acute Stroke
NO donors can be broadly categorised into organic (e.g.
GTN) and inorganic (e.g. sodium nitroprusside) nitrates,
although there are many subtypes [40]. Transdermal
GTN has been administered as a transdermal patch to
patients with acute and subacute stroke in three phase II
trials; GTN lowered BP (peripheral and central), 24-h
BP, peak systolic BP (SBP), pulse pressure and pulse
pressure index; increased heart rate; improved vascular
compliance; and did not alter cerebral blood flow and
velocity, or induce cerebral steal or increase intracranial
pressure (Table 1) [41–45]. While intravenous sodium
nitroprusside has antiplatelet properties [46], GTN had
no such impact on platelet function and can therefore be
administered in patients with ICH [41]. None of these
earlier studies were powered for efficacy, and this was
assessed in the large Efficacy of Nitric Oxide in Stroke
(ENOS) trial [47].
ENOS enrolled 4011 participants with acute stroke
(within 48 h of onset) and raised systolic BP
(140–220 mmHg) and randomised these to transdermal
GTN patch (5 mg) or no patch. Overall, there was no
significant shift in functional outcome measured using the
modified Rankin Scale at day 90 (primary outcome,
adjusted common odds ratio 1.01, 95% confidence intervals
[CI] 0.91–1.13) or of any secondary outcomes; further,
GTN was safe with no increased reporting of serious
adverse events [47]. GTN lowered BP by 7.0/3.5 mmHg as
compared with control at day 1. In a pre-defined subgroup
by time to randomisation (ENOS-early), those who
received GTN within 6 h of stroke onset had a favourable
shift in the modified Rankin Scale (adjusted common odds
ratio 0.51, 95% CI 0.32–0.80), less death, less disability
(Barthel Index), less mood disturbance (Zung Depression
Scale), and improved cognition (telephone Mini-Mental
State Examination) and quality of life (Euro-Quality of life
Visual Analogue Scale and Health Utility Scale) [48]. The
small ambulance-based Rapid Intervention with Glyceryl
trinitrate in Hypertensive stroke Trial (RIGHT) also found
that transdermal GTN 5 mg, given in the pre-hospital set-
ting by paramedics within 4 h of ictus, improved the
modified Rankin Scale at day 90 [49].
An individual patient data meta-analysis using data from
the five completed GTN trials (GTN-1/2/3, ENOS, RIGHT,
n = 4197) supported the findings that treatment with GTN
within 6 h of onset (n = 312), but not later, improved
functional outcome and secondary outcomes across a range
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of domains: cognition; death; disability; mood; and quality
of life (Table 2) [50]. The time-dependent effect on func-
tional outcome was seen in both IS and ICH; a finding
supported by a subgroup analysis of participants with ICH
from the ENOS trial [51]. Those with ICH who received
GTN within 6 h of onset had significant improvements in
functional outcome, cognition, disability, mood and quality
of life at 90 days compared with those who did not receive
GTN [51]. In the aforementioned meta-analysis, those with
IS who received thrombolysis, given either before or after
randomisation, had a significant shift to less death or
dependency in the presence of GTN. A tendency to
improved outcome was also seen in those with IS who did
not receive intravenous alteplase [50].
Further trials are needed to confirm whether GTN is
efficacious when given early in patients with acute stroke;
one study, the Rapid Intervention with Glyceryl trinitrate in
Hypertensive stroke Trial-2 (RIGHT-2), is assessing
transdermal 5-mg GTN patch vs. sham in 850 patients with
presumed stroke within 4 h of onset, SBP[120 mmHg and
FAST score 2 or 3; paramedics perform consent, recruit-
ment and treatment in the pre-hospital setting.
Table 1 Effects of GTN in acute/subacute stroke
GTN-1
2001 [41]
GTN-2 2003
[42]
GTN-3 2006
[43]
RIGHT 2013 [49] ENOS 2015 [47] GTN
1-2
[45]
GTN
1-3
[44]
Systolic BP
(mmHg)
; 13
(7.8%)
; 23 (14%) ; 21 ; 7 ; 9.4 ; 9.8
Diastolic BP
(mmHg)
; 5.2
(5.4%)
; 4 (3%) ; 6 ; 3.5 ; 4.8 ; 4.4
Heart rate
(bpm)
No
change
No change No change No change : 1.7 : 4.1 : 3.9
MAP (mmHg) ; 6.2% ; 5.0 ; 6.4
PP (mmHg) ; 3.9 : 16 ; 6.1
PPI ; 0.03
RPP
(mmHg.bpm)
No change ; 323
Augmentation
index
Improved Improved
Cerebral blood
flow velocity
No change No change
Cerebral blood
flow
No change
Zero flow
pressure
No change
Platelet
function
No
change
GTN supplier
(5 mg)
Schwarz
Pharma
Schwarz Pharma
(5 and 10 mg)
Novartis
(Transiderm-
Nitro)
MSD Schering-
Plough
(NitroDur)
UCB Pharma (Deponit-5) in
38% of sites (29%a)
Novartis (Transiderm-Nitro) in
28% of sites (34%a)
MSD/Schering-Plough
(NitroDur) in 25% of sites
(19%a)
Meda/3M Healthcare (Minitran)
in 10% of sites (3%a)
Wuhan Jianmin in 1% of sites
(2%a)
BP blood pressure, bpm beats per minute, ENOS Efficacy of Nitric Oxide in Stroke trial, GTN glyceryl trinitrate,MAP mean arterial pressure, PP
pulse pressure, PPI pulse pressure index, RIGHT Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial, RPP rate pressure
product, ; indicates a decrease, : indicates an increase
a Percentage of sites for ENOS-early (within 6 h)
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3 Mechanisms of Action of Glyceryl Trinitrate
in Acute Stroke
If transdermal GTN is found to be beneficial in the man-
agement of acute stroke, there are several potential mech-
anisms through which its actions may be mediated
(Table 3). First, BP lowering may reduce early recurrent
events in IS [29] and haematoma expansion in ICH [30].
The ability of GTN to lower BP without reducing CBF or
cerebral perfusion pressure, or increasing intracranial
pressure, may be due to its vasodilatory effect thus
increasing blood flow exiting the cranium [43]. Second, in
addition to high SBP being associated with poor clinical
outcomes in acute stroke, other haemodynamic variables
including higher peak SBP, mean arterial pressure, pulse
pressure, pulse pressure index and increased SBP vari-
ability are independently associated with worse functional
outcome, death, recurrent stroke and early neurological
deterioration [52–54]. The published effects of GTN on
haemodynamic measures in acute stroke are detailed in
Table 1. New data on SBP variability from the four pilot
studies (GTN 1-3 and RIGHT) are included in Table 4.
Between-visit systolic BP variability was calculated as
standard deviation (SD) and coefficient of variation
(CoV = SD/mean) of SBP over days 1–7 across each trial
individually and across all four trials as a whole. The mean
difference between GTN and no GTN was calculated using
analysis of covariance with adjustment for baseline SBP
and trial as appropriate. GTN reduced SBP variability (SD
and CoV) over days 1–7 when given within 4 h in the
RIGHT pre-hospital trial in both adjusted and unadjusted
analyses. When pooled together, there was significant
heterogeneity seen across the trials for both SD (I2 = 75%)
and CoV (I2 = 79%). This heterogeneity likely represents
the small sample sizes of each of the trials and the varying
time from stroke onset to randomisation. Therefore,
Table 2 Clinical outcomes
with GTN in acute stroke [50]
All GTN Randomisation B6 h
Patients (%) 4197 312 (7.4)
End of treatment
Death 1.15 (0.79, 1.68) 0.94 (0.23, 3.81)
Neurological deterioration 1.29 (1.00, 1.66) 0.58 (0.28, 1.23)
Stroke recurrence 1.39 (0.88, 2.18) 0.46 (0.14, 1.54)
SSS (/58) 0.33 (-0.26, 0.91) 2.33 (-0.42, 5.09)
NIHSSa -0.28 (-0.70, 0.14) -2.07 (-3.81, -0.34)
Day 7
Non-oral feedinga 0.97 (0.82, 1.15) 0.59 (0.32, 1.08)
Hospital
Length of stay (days) 0.07 (-1.30, 1.44) 0.02 (-4.59, 4.63)
Physiotherapya 0.94 (0.79, 1.12) 0.90 (0.40, 2.05)
Occupational therapya 1.01 (0.72, 1.41) 1.15 (0.36, 3.68)
Speech therapya 0.95 (0.84, 1.08) 1.01 (0.44, 2.29)
Day 90
Modified Rankin Scale 0.99 (0.89, 1.10) 0.52 (0.34, 0.78)
Death 0.87 (0.71, 1.07) 0.32 (0.14, 0.78)
Barthel Index 1.73 (-0.08, 3.55) 9.64 (3.19, 16.09)
Quality of life (HUS) 0 (-0.02, 0.02) 0.05 (-0.02, 0.13)
Quality of life (EQ-VAS) 0.69 (-1.06, 2.43) 5.97 (-0.30, 12.24)
Mood (ZDS) -0.38 (-1.80, 1.04) -8.34 (-13.32, -3.36)
Cognition (t-MMSE) 0.34 (-0.16, 0.84) 2.09 (0.65, 3.54)
Cognition (TICS-M) 0.16 (-0.55, 0.88) 3.56 (1.20, 5.91)
Cognition (animal naming) -0.06 (-0.60, 0.47) 1.63 (-0.13, 3.39)
Data are number (%), mean difference, or odds ratio with 95% confidence intervals. Comparisons by binary
logistic regression, ordinal logistic regression or multiple linear regression, with adjustment for trial.
Significant (p\ 0.05) results are in bold
BI Barthel Index, EQ-VAS Euro-Quality of life Visual Analogue Scale, GTN glyceryl trinitrate, HUS Health
Utility Scale (derived from Euro-Quality of life 5-dimensions (EQ5D)), NIHSS National Institutes of Health
Stroke Scale, SSS Scandinavian Stroke Scale, TICS-M Telephone Interview Cognition Scale, t-MMSE
Telephone Mini-Mental State Examination, ZDS Zung Depression Scale
a Unadjusted using the Mantel–Haenszel random-effects model
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adjustment was made for baseline SBP and trial, after
which GTN significantly reduced SBP variability (SD)
compared with no GTN. Pre-specified secondary analysis
of haemodynamic parameters in ENOS is awaited [55].
Third, the time dependency of early treatment with GTN
is akin to that seen in both thrombolysis and endovascular
therapy, so-called reperfusion treatments [56, 57]. As
described, GTN is a potent vasodilator, which may have
effects in different parts of the vascular tree: large cerebral
arteries, increasing ‘front door’ and peri-lesional perfusion
without inducing cerebral steal [43]; and surface pial
arteries, increasing collateral (‘back door’) perfusion [58].
Fourth, in the context of thrombolysis, GTN may be syn-
ergistic through vasodilatation of the occluded or partially
occluded artery, which may allow exogenous and
endogenous thrombolytic compounds better access to clot.
Table 3 GTN in acute stroke: mechanisms of action and unanswered questions
Issue Prior observations Comment
Time Reperfusion therapies exhibit time dependency:
thrombolysis [56] and thrombectomy [57]
Apparent time-dependent effect mirrors thrombolysis and
thrombectomy
Stroke type
Ischaemic
stroke
BP lowering may reduce recurrent events Apparent benefit: vasodilatory effects may improve blood flow in
large arteries (‘front door’) [43] and pial arteries/collaterals
(‘back door’) [58]; new data awaited
Intracerebral
haemorrhage
BP lowering may reduce haematoma expansion [65] Apparent benefit; new data awaited
Stroke syndrome
Lacunar Unclear effect; further analyses and new data awaited
Total anterior
circulation
Apparent benefit: tendency for improved functional outcome in
total anterior circulation in ENOS [47]; further analyses and new
data awaited
Stroke severity
Severity Apparent benefit: tendency for improved functional outcome in
severe stroke in ENOS [47]; further analyses and new data
awaited
Safety
Carotid
stenosis
BP lowering might reduce perfusion Initial safety seen in all levels of ipsilateral carotid stenosis in
ENOS [47]; further analyses and new data awaited
Large vessel
occlusion
Unknown; further analyses and new data awaited
Dehydration
and stroke
Large drops in BP may occur in dehydrated patients
given antihypertensive medication
Relevance to GTN unknown; further analyses and new data
awaited
Stroke mimics No adverse effect seen in RIGHT [49]; new data awaited
Duration of
therapy
Tachyphylaxis seen in GTN-1/2 and ENOS [41, 42, 47]. RIGHT-2
is assessing 4 days of treatment whilst planned trials will assess 1
or 2 days of treatment
Route of
administration
Transdermal drugs allow easy application and removal
without need for swallowing assessment or
intravenous access
GTN given by transdermal patch
Pre-stroke BP-
lowering
therapy
Antihypertensive medication is regularly taken prior to
stroke [47]
No interaction between this and GTN seen in ENOS [47]
Haemodynamics
BP
derivatives
Increased MAP, PP, PPI, peak SBP and SBP variability
are associated with poor outcomes
GTN reduces MAP, PP, PPI, peak SBP and variability [44, 55]
Heart rate High heart rate [54] and impaired heart rate variability
[66] are associated with worse outcome
GTN increases heart rate by 2–4 beats per minute. Tendencies to
reduced rate pressure product (RPP = SBP 9 HR) suggest that
the effect of GTN on HR is more than offset by BP reduction
[44]; further analyses and new data awaited. Effect on heart rate
variability to be ascertained
BP blood pressure, ENOS Efficacy of Nitric Oxide in Stroke trial, GTN glyceryl trinitrate, MAP mean arterial pressure, PP pulse pressure, PPI
pulse pressure index, RIGHT2 Rapid Intervention with Glyceryl trinitrate in Hypertensive Stroke Trial-2, SBP systolic BP
Therapeutic Potential of Transdermal GTN in the Management of Acute Stroke
GTN also appears to prepare patients for thrombolysis by
lowering systolic BP below the licensed threshold of
185 mmHg. A non-significant increase in both rates of
thrombolysis and earlier treatment was seen in RIGHT
[49]. Last, the neuroprotective effects of GTN mediated via
NO may prevent cell death from ischaemia [10, 18].
4 Unanswered Questions
Although ENOS confirmed the overall safety of GTN in
acute stroke [47], several distinct scenarios warrant further
discussion (Table 3). First, patients with carotid stenosis as
the cause of their stroke often have high BP at presentation
and whether to lower their BP is subject to debate. Owing to
dysfunctional cerebral autoregulation, higher BP leads to
higher cerebral perfusion pressure, increasing the risk of
cerebral oedema and haemorrhagic transformation of
infarction, whilst BP reduction may compromise CBF
extending infarction [30]. Across all levels of ipsilateral
carotid artery stenosis within ENOS (2038 participants with
carotid imaging data), GTN was safe with no evidence of
harm [47]. However, data for patients with severe bilateral
carotid stenosis are sparse, given its rarity, although a meta-
analysis of three trials found that lower BP was associated
with increased stroke recurrence [59]. In this group, BP
lowering should be avoided pending further data. A post-
hoc analysis of the ENOS dataset is planned for further
clarification of this important patient subgroup. Second, and
similarly, the advent of endovascular therapy for proximal
anterior circulation vessel occlusions in acute IS poses
several challenges including how to manage BP without
potentially compromising CBF; the ongoing RIGHT-2 trial
will include a subgroup of patients who have thrombectomy
following GTN-sham treatment. Third, dehydration is a
common finding in patients with acute stroke and was
associated with poor outcomes in a stroke registry study
[60]. BP lowering in the setting of dehydration may lead to
precipitous drops in BP, which could be harmful; the effect
of GTN in this scenario is unclear and a subgroup analysis
of ENOS may prove illuminating. Last, the administration
of an agent that may improve outcome when given as early
as possible will inevitably mean that patients with condi-
tions mimicking stroke will receive treatment. Therefore, it
is imperative that GTN is safe in this group; a question for
ongoing and future trials.
As previously alluded to, GTN positively influenced
several clinical outcomes when given early in both IS and
ICH [50].Whether GTN has the same effects in patients with
lacunar syndromes, lacunar strokes or small vessel disease is
unclear and further analysis is required. In addition to
answering these and other questions, current and future trials
will need to record data on other outcomes includingT
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thrombolysis, thrombectomy, neurosurgical procedures (e.g.
hemicraniectomy), feeding status, therapy usage and length
of stay (overall, intensive care unit), as these may be influ-
enced by the efficacy of GTN. Indeed, early GTN was
associated with less nasogastric and more oral feeding in
ENOS-early (unpublished). Importantly, all the trial data for
GTN in acute stroke are from one group of authors; others
need to replicate and confirm these findings in differing
countries, healthcare settings and stroke populations.
5 Glyceryl Trinitrate in Acute Stroke: What Does
the Future Hold?
There are few evidence-based treatments for the manage-
ment of acute stroke. In acute IS, intravenous thrombolysis
[56], thrombectomy [61] and decompressive hemicraniec-
tomy [62] each have high efficacy but low utility, whilst
aspirin has high utility but low efficacy [63]. Managing
patients with all stroke types in stroke units has very high
utility with medium-level efficacy [64]. In comparison,
GTN has high utility, low cost (£5/$7 per patient), is easily
administered and should be easy to implement if efficacy is
confirmed. Importantly, the source of the patch does not
influence efficacy; participants within ENOS (including
those randomised within 6 h) received patches from dif-
ferent manufacturers, whilst the other GTN trials used one
manufacturer to supply each trial (Table 1).
In the future, GTN could be used on a global scale in
developing and developed countries, rural and urban areas,
before and in hospital, and in a variety of healthcare set-
tings. The possibility of an inexpensive and effective
intervention for the management of acute stroke is a wel-
come prospect in the current economic climate.
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